Have been reading this post and researching with some interest....

Have been reading this post and researching with some interest. I might be reading the posts incorrectly, but the general feeling I am getting was that ONT-10 and Stimuvax may be in competition with Cvac. This raises several points.

Both ONT-10 and Stimuvax target MUC-1, which is what PRR are targeting. So, even if they are successful, it will be a financial windfall for PRR, as PRR has 4 family Patents around MUC-1, in respect of targeting it for cancer. Here is the link:

http://www.thefreelibrary.com/PRIMA+BIOMED+SECURES+KEY+CANCER+PATENT+IN+U.S.-a0103446136

So, PRR should, IMHO, receive some royalties if they prove successful.

The second point is that Oncothyreon (which used to be called Biomira, who PrimaBiomed was working with in 2007), must feel that PRR is on a winner with MUC-1, otherwise they would not be pursuing it.
Either way, I think it would be a win win for PRR

GLTA